Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03101475
Title Synergism of Immunomodulation and Tumor Ablation (ILOC)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors European Organisation for Research and Treatment of Cancer - EORTC

colorectal cancer


Durvalumab + Tremelimumab

Age Groups: senior | adult
Covered Countries FRA | DEU | AUT

Facility Status City State Zip Country Details
Medical University Vienna - General Hospital AKH Vienna Austria Details
Institut Bergonie Bordeaux France Details
Universitaetsklinikum Carl Gustav Carus Dresden Germany Details
Universitaetsklinikum Leipzig-Ambulanzen/Sprechstunden Leipzig Germany Details
The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis Amsterdam Netherlands Details
Radboud University Medical Center Nijmegen Nijmegen Netherlands Details
Karolinska University Hospital - Karolinska Institutet - Danderyds Hospital Stockholm Sweden Details
Inselspital Bern Switzerland Details
Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie Geneva Switzerland Details
UniversitaetsSpital Zurich Zürich Switzerland Details
*Shaded cells indicate that there was no data available from for the field